FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention relates to drug forms domain, particularly to thermoformed by extrusion without colour altering, protected from unintended application, dosage form, which includes active substance, potentially subject to non-medical abuse, and auxiliaries; it also contains synthetic or natural polymer with at least 500 N breaking strength. Moreover production method for such drug form is described.
EFFECT: providing of protection from non-medical internal applications.
35 cl, 1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL FORM PROTECTED AGAINST NON-INTENDED USE | 2004 |
|
RU2354357C2 |
| PROTECTED AGAINST UNADMINISTERED APPLICATION PERORAL MEDICATION FORM | 2005 |
|
RU2396944C2 |
| DOSAGE FORM PROTECTED FROM UNINTENDED USE AND CONTAINING (1R, 2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL | 2005 |
|
RU2393847C2 |
| DEGRADATION-RESISTANT DOSAGE FORM WITH DELAYED RELEASE OF OXYCODONE HYDROCHLORIDE | 2010 |
|
RU2461381C2 |
| EXTENDED RELEASE DURABLE DOSAGE FORMS | 2006 |
|
RU2399371C2 |
| SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | 2013 |
|
RU2673818C2 |
| PHARMACEUTICALLY ACCEPTABLE SOLUBILISING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING IT | 2007 |
|
RU2469708C2 |
| DESTRUCTION-RESISTANT DOSAGE FORM CONTAINING AN INORGANIC SALT | 2011 |
|
RU2604676C2 |
| PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
| TRICYCLIC BENZODIAZEPINES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND METHODS FOR HYPERTENSION TREATMENT | 1999 |
|
RU2250899C2 |
